Regeneron Pharmaceuticals, Inc. (REGN) announced encouraging initial results from two cohorts of the early-stage study on oncology drug linvoseltamab.LINKER-MM2 is a phase Ib, open-label clinical trial evaluating linvoseltamab in combination with other cancer treatments in patients with relapsed/refractory (R/R) multiple myeloma (MM).  Results presented that linvoseltamab in combination with carfilzomib or bortezomib showed promising results in earlier lines of treatment for relapsed/refractory multiple mye ...

First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM). The trial included patients who ...

Core Insights - Regeneron Pharmaceuticals is recognized for its strong R&D capabilities and has a promising pipeline of products expected to be released in the next 6 to 12 months [1] Company Overview - The discussion features key company representatives, including George D. Yancopoulos, who serves as Board Co-Chair, President, and Chief Scientific Officer, and Mark Hudson, Senior Director of Investor Relations [1][2] - The conference is part of the RBC Capital Markets Global Healthcare Conference, indicating the company's engagement with investors and analysts [1] Upcoming Developments - A significant upcoming catalyst for Regeneron is the Phase 3 data for Itepekimab related to Chronic Obstructive Pulmonary Disease (COPD), which is anticipated to provide insights based on previous data from asthma and COPD studies [5]

Regeneron Pharmaceuticals (REGN) Conference Call Summary Company Overview - **Company**: Regeneron Pharmaceuticals (REGN) - **Date**: May 20, 2025 - **Key Speakers**: George Hancopoulos (Co-Chair, President, CSO), Mark Hudson (Senior Director of IR) Key Industry Insights R&D and Pipeline Developments - Regeneron is recognized for its robust R&D capabilities, with significant upcoming catalysts expected in the next six to twelve months [2][5] - The company has a strong pipeline, particularly in the areas of asthma and Chronic Obstructive Pulmonary Disease (COPD) [6][14] Clinical Trial Success - Regeneron has achieved success in eight out of eight Phase III trials for Dupixent, highlighting the effectiveness of their technology and understanding of biology [8][12] - The company emphasizes the importance of high-throughput technologies in antibody development, screening millions of antibodies to identify the best candidates [10][12] Genetic Insights and Disease Targeting - Regeneron utilizes a unique genetic database to inform its drug development, allowing for targeted approaches based on genetic variations that impact disease [12][39] - The company has identified specific genetic pathways associated with diseases like asthma and COPD, which guide their clinical focus [13][39] Product-Specific Insights Dupixent (Dupilumab) - Dupixent has shown over 30% reductions in exacerbations for eosinophilic COPD patients, setting a high bar for treatment efficacy [15][21] - For low eosinophil patients, a target of a 20% reduction in exacerbations is considered significant due to the lack of treatment options [15][16] Oncology Developments - Regeneron is excited about its oncology portfolio, particularly Libtayo (a PD-1 inhibitor) and its combination with LAG-3 fianlimab, which is expected to yield Phase III data in first-line metastatic melanoma [22][28] - The company has achieved higher complete response rates with its BCMA bispecific for myeloma compared to competitors, indicating strong potential in earlier treatment settings [21][23] Factor XI Antibodies - Regeneron is developing two antibodies targeting Factor XI, aiming to provide safer anticoagulation options with reduced bleeding risks compared to traditional therapies [31][34] - The focus is on balancing efficacy with safety to broaden the use of anticoagulants across various patient populations [36][37] Strategic Collaborations and Acquisitions - Regeneron is acquiring 23andMe to enhance its genetic research capabilities, aiming to leverage this data for broader societal health benefits [45][46] - The company believes that its investment in genetic databases differentiates it from competitors and empowers its drug development efforts [40][41] Future Outlook - Regeneron is committed to advancing its pipeline and exploring next-generation versions of existing products like Dupixent, leveraging its historical success in the industry [49][52] - The company aims to continue leading in the development of best-in-class therapies across various therapeutic areas, including oncology and genetic diseases [52][53]

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the majority of assets of 23andMe Holding Co. in a bankruptcy auction, planning to acquire key business units for $256 million [1][2]. Company Acquisition Details - Regeneron intends to acquire 23andMe's Personal Genome Service, Total Health and Research Services business units, Biobank, and related assets, while 23andMe will become a wholly-owned subsidiary of Regeneron [2]. - The acquisition does not include 23andMe's Lemonaid Health business [2]. - The deal is subject to bankruptcy court approval, regulatory clearances, and other customary closing conditions, with completion expected in Q3 2025 [3]. Strategic Benefits - The acquisition is expected to enhance Regeneron's genetics-based drug discovery efforts by integrating 23andMe's consumer genomic services with its research capabilities [6]. - Regeneron aims to leverage the acquired genetic data to drive drug discovery and development, particularly in areas such as cancer, infectious diseases, and immune disorders [4][6]. Commitment to Privacy - Regeneron has committed to maintaining 23andMe's consumer privacy standards and complying with data protection laws, ensuring transparency regarding the use of customer data [7].

Core Viewpoint - Regeneron Pharmaceuticals is acquiring 23andMe out of bankruptcy for $256 million, gaining access to a significant collection of genetic data and samples from over 15 million customers, which raises privacy concerns [1][4]. Company Acquisition Details - The acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and its biobank [1]. - The deal is expected to close in the third quarter of 2025, pending bankruptcy court and regulatory approvals [2]. Privacy and Compliance - Regeneron has committed to adhering to 23andMe's consumer-privacy rules and will collaborate with a court-appointed ombudsman to ensure compliance [3]. - The company aims to protect the dataset with high standards of data privacy and security [3]. Background on 23andMe - 23andMe was once valued at over $6 billion after going public in 2021 but has since dropped to a valuation of approximately $50 million due to various issues, including a $30 million settlement related to a data breach affecting nearly 7 million users [4][5]. - The company filed for bankruptcy in March, prompting the California Attorney General to advise customers to delete their data from 23andMe's database [5][8]. Leadership Changes - Anne Wojcicki, co-founder and CEO of 23andMe, stepped down on the day of the bankruptcy filing following internal conflicts with the board [9]. - All seven independent board members of 23andMe resigned in September, indicating significant governance issues within the company [9].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - Proactive employs technology to enhance workflows and has a forward-looking approach to technology adoption [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the assets of 23andMe Holding Co. for $256 million, aiming to enhance its leadership in genetics-guided research and drug development, pending bankruptcy court and regulatory approvals [1][2][3] Group 1: Acquisition Details - The planned acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and Biobank assets, with the transaction expected to close in Q3 2025 [1] - Regeneron will operate 23andMe as a wholly owned subsidiary, continuing its consumer genomics services while excluding the Lemonaid Health business from the purchase [3][4] Group 2: Commitment to Data Privacy - Regeneron emphasizes its commitment to the privacy and ethical use of 23andMe's customer data, planning to work with an independent Customer Privacy Ombudsman to ensure compliance with privacy policies and laws [2][3] - The company has a proven track record in large-scale data management, having linked deidentified DNA sequences from nearly three million participants to electronic health records [2][3] Group 3: Strategic Vision - Regeneron aims to leverage its expertise in genetic research to support 23andMe's mission of helping individuals understand their DNA and improve personal health [2][3] - The acquisition aligns with Regeneron's broader strategy to utilize genetics research for advancing medical treatments and improving societal health outcomes [2][3][4]

Core Points - Adam Kovalčík, a 19-year-old from Slovakia, won the $100,000 George D. Yancopoulos Innovator Award for developing a cost-effective method to produce the antiviral drug galidesivir, reducing production costs from $75/gram to approximately $12.50/gram [1][3] - The Regeneron International Science and Engineering Fair (ISEF) awarded over $9 million in scholarships and prizes, showcasing nearly 1,700 young scientists from 48 U.S. states and over 60 countries [2][8] - Other notable projects included a desktop plastic recycling system, a device for detecting toxic dusts, and a brain-controlled bionic prosthetic leg, highlighting innovation in sustainability and health technology [4][5][6] Company Insights - Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on developing life-transforming medicines for serious diseases, with a strong emphasis on scientific innovation and education [37][38] - The company has been actively involved in promoting STEM education, having provided experiences to over 3.2 million students since 2020, surpassing its goal of 2.5 million by 2025 [8] - Regeneron's commitment to corporate responsibility includes fostering a culture of integrity and excellence, as well as significant philanthropic efforts in science education [38]

Core Viewpoint - A federal court jury found Amgen liable for antitrust violations, awarding Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages due to Amgen's anticompetitive practices that hindered competition for Praluent [1][3]. Summary by Relevant Sections Antitrust Violations - Amgen was found to have violated multiple laws, including the Clayton Act and Sherman Act, by using cross-therapeutic bundled rebates to favor Repatha over Praluent, thereby preventing fair competition [1][2]. Jury Verdict and Damages - The jury awarded Regeneron a total of $406.8 million, comprising $135.6 million in compensatory damages and $271.2 million in punitive damages aimed at deterring similar future conduct [3]. Company Statements - Regeneron emphasized the importance of fair competition in the biotech industry, stating that anticompetitive tactics undermine patient access to innovative therapies and hinder medical advancements [4]. Product Information - Praluent, developed by Regeneron and Sanofi, is designed to lower LDL cholesterol levels by inhibiting PCSK9, and is approved in 60 countries [6][7]. Technology and Innovation - Regeneron's proprietary VelocImmune technology has been instrumental in developing fully human monoclonal antibodies, contributing to a significant portion of FDA-approved treatments [8][9].